SureTrader Advertisement Advertisement Advertisement
Home > Boards > US Listed > Medical - Drugs >

Transgenomic Inc. (TBIO)

Add TBIO Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 10/5/2015 3:39:17 PM - Followers: 27 - Board type: Free - Posts Today: 5


Link to coporate website:

Share Structure
Market Value1 $40,142,705 a/o May 10, 2013
Shares Outstanding 88,225,725 a/o Mar 13, 2013
Float Not Available
Authorized Shares 100,000,000 a/o Aug 02, 2011
Par Value 0.01

Wells Fargo Bank Minnesota, N.A.
Shareowner Services
P.O. Box 64854
St. Paul, MN 55164-0854
Phone: 877-602-7611

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Our offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine.

Transgenomic offers its WAVE® DHPLC Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification and have broad applicability to genetic research. To date there have been over 1600 systems shipped to more than 30 countries.

Transgenomic's SURVEYOR® Mutation Detection Kits and the SURVEYOR Check-It Kit provide reagents and protocols for the detection of mutations in DNA.

Transgenomic's Cytogenetics offering includes HANABI automated chromosome harvesting systems that improve laboratory productivity with consistent quality compared to manual methods.

Transgenomic Clinical Reference Laboratory provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases.

Transgenomic Genomic Research Services is a CRO for pharmacogenomic, translational research and clinical trials.

Colorectal Cancer Testing

Very important AMGEN signs collaberation deal with Mgmt:

"Another potential meaningful near-term contributor to the Lab Services segment (as well as to the Diagnostic Tools segment) relates to the recently consummated agreement with Amgen (NasdaqGS:AMGN) whereby the two companies are collaborating on a KRAS an NRAS gene mutation assay kit to screen patients for colorectal cancer.  The RAScan test is currently available for research use only (RUO) in the U.S. (which will run through Lab Svcs) and for clinical use in Europe - which could help accelerate instrument placements (through Menarini) as well as increase consumables sales"

CRC RAScan™ is a new mutation detection test designed to screen for selected KRAS and NRAS mutations (collectively referred to as “RAS mutations”), in patients with metastatic colorectal cancer (mCRC).The identification of these RAS mutations can give physicians important clinical information to help them make better treatment decisions for their mCRC patients.

KRAS and NRAS are part of the RAS family of genes which encode proteins involved in transmitting signals within cells. When Ras proteins are “switched on” by incoming signals, other genes involved in cell growth, differentiation, and survival are activated. Mutations in KRAS, NRAS and other related genes can lead to Ras proteins becoming permanently activated, causing overactive signaling even in the absence of incoming signals, and can lead to the uncontrolled cell growth that characterizes cancer. Mutations that permanently activate Ras proteins are found in ~25% of human tumors and up to 90% of certain cancers. About 40% of colorectal tumors carry KRAS gene mutations and these mutations have been associated with poor response to EGFR antagonists such as cetuximab and panitumumab. Therefore KRAS mutation status can be used to determine whether or not a patient with colorectal cancer will respond to anti-EGFR therapy.

The CRC RAScan test can identify mCRC patients who have RAS mutations at levels that cannot be detected using traditional Sanger Sequencing methods.

CRC RAScan™ for Colorectal Cancer Tumor Testing is available immediately from Transgenomic’s CLIA-certified laboratory in the United States. For more information on this test, click here.

CRC RAScan Mutation Detection Kits will soon be available in the U.S for research use only. CRC RAScan Mutation Detection Kits include the following kits based on Transgenomic's proprietary SURVEYOR® Nuclease technology:

  • KRAS Exon 2
  • KRAS Exons 3 & 4
  • NRAS Exons 2, 3 & 4

Zacks analyst ~ OUR 2013 OUTLOOK~

We've again made some updates to our model.  We now model 2013 revenue of $32.4 million, implying growth of 3% from 2012.  We look for Laboratory Services and Instruments to generate revenue of $20.0 million (+4%) and $12.4 million (+2%), respectively.  We think net income and EPS come in at ($12.7) million and ($0.14).


New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of clinical response to Vectibix, activating mutations in KRAS (beyond exon 2) and mutations in NRAS, collectively referred to as RAS.

"Amgen helped establish KRAS gene mutation as a biomarker for lack of response to anti-EGFR treatment," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The identification of new biomarkers may further help to identify appropriate patients with this incurable disease for such treatment."


Contact Information:
Phone: (402) 452-5437

SEC Filings:

Press Releases:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#778   Stacking the ask now to make sure this Tstorm 10/05/15 03:39:17 PM
#777   Market Maker EDGX is the one who does Tstorm 10/05/15 03:38:20 PM
#776   Classic example, 1400 on the bid at .92. Tstorm 10/05/15 03:22:37 PM
#775   Be careful, no bid support right now so Tstorm 10/05/15 10:23:56 AM
#774   Already up on no news. alphaInvestor2 10/05/15 09:31:43 AM
#773   You guys are way too hard on Kinnon. laser777 10/02/15 08:10:19 AM
#772   We still need legit news for this to alphaInvestor2 10/01/15 07:36:54 PM
#771   Today was the first piece of positive trading Tstorm 10/01/15 05:48:12 PM
#770   Looks like Kinnon has more to benefit from alphaInvestor2 10/01/15 04:00:11 PM
#769   They are going to run this down to zero....... Tstorm 10/01/15 11:11:38 AM
#768   No bid support whatsoever....... Tstorm 10/01/15 10:40:28 AM
#767   Scary - no end in sight! Tstorm 09/30/15 04:51:17 PM
#766   Your recent re-post of YMBs DD did not alphaInvestor2 09/30/15 11:33:51 AM
#765   The news is still positive as they are laser777 09/30/15 11:27:07 AM
#764   .96 printing now, some hope here today. Must Tstorm 09/30/15 11:15:10 AM
#763   Did you expect any different? We alphaInvestor2 09/30/15 11:02:57 AM
#762   NEWS - Reduces the burn rate by 1.2 Tstorm 09/30/15 10:17:40 AM
#761   Looks like our IHUBBERS sold out this AM Tstorm 09/30/15 10:16:28 AM
#760   WOW going much lower today once again.... Tstorm 09/30/15 10:09:44 AM
#759   NEWS -Transgenomic Signs Binding Term Sheet to Divest Tstorm 09/30/15 09:44:39 AM
#758   Wow i expected some strength today.... it doesn't Tstorm 09/30/15 09:38:12 AM
#757   Alpha i agree with your email...I have my Tstorm 09/29/15 10:59:39 PM
#756   As i said this is toxic right now. Tstorm 09/29/15 10:04:21 PM
#755   Post from YMB.... laser777 09/29/15 05:58:01 PM
#754   This is my hope also. Then all this laser777 09/29/15 04:55:07 PM
#753   I think you are on to something and alphaInvestor2 09/29/15 04:50:59 PM
#752   If this is the case then management needs Tstorm 09/29/15 03:02:28 PM
#751   This needs to be near the top on laser777 09/29/15 02:54:22 PM
#750   This is brutal alphaInvestor2 09/29/15 02:52:08 PM
#749   bid at .78 now! Tstorm 09/29/15 02:38:56 PM
#748   All bid support gone, Kinnon your a POS...... Tstorm 09/29/15 02:38:38 PM
#747   Massive dumping now, going below .90 today and Tstorm 09/29/15 02:35:35 PM
#746   Im sorry for all of us here. This Tstorm 09/29/15 02:06:16 PM
#745   Huge blocks going through the bid now.... Escalation Tstorm 09/29/15 02:04:43 PM
#744   Like the old adage goes, if it sounds alphaInvestor2 09/29/15 01:06:39 PM
#743   I should have shorted this alphaInvestor2 09/29/15 01:05:31 PM
#742   Biotech up 3.5% today - TBIO down 3.8% Tstorm 09/29/15 11:40:59 AM
#741   Wow .99 now... Tstorm 09/29/15 11:38:45 AM
#740   So 5 orders hit the ask and the Tstorm 09/29/15 11:10:42 AM
#739   5 orders just hit the ask at 1.04 Tstorm 09/29/15 11:09:28 AM
#738   Undercutting continues... Could have been trading at 1.10 Tstorm 09/29/15 09:43:46 AM
#737   Call them and leave a message. Kinnon alphaInvestor2 09/28/15 04:53:16 PM
#736   Believe me i hope i`m wrong but the Tstorm 09/28/15 04:26:06 PM
#735   I agree, But why has the stock price Tstorm 09/28/15 04:22:00 PM
#734   Just being the devils advocate, but would that laser777 09/28/15 03:31:28 PM
#733   I think there has been a ton of laser777 09/28/15 03:16:38 PM
#732   This is just to scare people out before alphaInvestor2 09/28/15 01:15:08 PM
#731   Now trading at .09 pre-split level... Great job Tstorm 09/28/15 11:03:33 AM
#730   This is way beyond where i thought this Tstorm 09/28/15 10:19:07 AM
#729   This is downright ugly alphaInvestor2 09/28/15 10:03:05 AM